2022 Spravato Drug Market Forecast Report to 2032 – Insights on Mechanism of Action, Dosage and Administration – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–Added “SPRAVATO Drug Insight and Market Forecast – 2032” drug pipeline ResearchAndMarkets.com Offer.

This report provides comprehensive insights into SPRAVATO for treatment-resistant depression in seven key markets.

A detailed picture of the SPRAVATO for treatment-resistant depression at 7MM i.e. USA, EU5 (Germany, France, Italy, Spain and UK) and Japan for the study period 2019-2032 is included in this report with a detailed description of the SPRAVATO for treatment-resistant depression .

The report provides insights into mechanism of action, dosing and administration, and research and development, including regulatory milestones, along with other development activities. Additionally, it also includes future market assessments including SPRAVATO Treatment-Resistant Depression Market Forecast Analysis in 7MM, SWOT, Analyst Opinions, a high-level view of market competitors and a brief overview of other emerging therapies for Treatment-Resistant Depression.

Drug summary

Spravato contains esketamine hydrochloride, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. Esketamine is the S-enantiomer of racemic ketamine. The chemical name is (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride. Its molecular formula is C13H16ClNO.HCl and its molecular weight is 274.2.

Esketamine hydrochloride is a white or almost white crystalline powder, freely soluble in water and methanol and soluble in ethanol. Spravato Nasal Spray is intended for nasal administration. Esketamine hydrochloride is contained in the nasal spray as a solution in a glass vial with a stopper. Each device delivers two puffs totaling 32.3 mg esketamine hydrochloride (equivalent to 28 mg esketamine) in 0.2 ml of a clear, colorless aqueous solution with a pH of 4.5

scope of the report

The report provides insights into:

  • A comprehensive product overview including SPRAVATO description, mechanism of action, dosage and administration, research and development activities in treatment-resistant depression.

  • Full details of SPRAVATO regulatory milestones and other development activities have been provided in this report.

  • The report also highlights SPRAVATO’s research and development activities in the field of treatment-resistant depression in the United States, Europe and Japan.

  • The report also includes the patent information with expiration timetable by SPRAVATO.

  • The report includes projected sales of SPRAVATO for treatment-resistant depression through 2032.

  • Comprehensive coverage of the late-stage evolving therapies for treatment-resistant depression.

  • The report also includes the SWOT analysis with analyst views for SPRAVATO in Treatment-Resistant Depression.

This report provides a detailed market assessment of SPRAVATO for treatment-resistant depression in seven major markets ie the United States, the EU5 (Germany, France, Italy, Spain and the UK) and Japan. This segment of the report includes forecast sales dates from 2019 to 2032.

report highlights

  • In the coming years, the market scenario for Treatment-Resistant Depression is going to change owing to the extensive research and increasing healthcare spending around the world; which would expand the market to allow drug manufacturers to penetrate the market more.

  • The companies are developing therapies focused on novel approaches to treat/improve the disease state, assessing challenges and exploring opportunities that could impact SPRAVATO’s dominance.

  • Other new products for treatment-resistant depression are expected to bring SPRAVATO fierce competition in the market, and the launch of new late-stage therapies in the near future will impact the market significantly.

  • A detailed description of regulatory milestones and development activities is provided by SPRAVATO’s current development scenario in treatment-resistant depression.

  • This in-depth analysis of SPRAVATO’s projected sales data from 2019 to 2032 will assist clients in making decisions regarding their therapeutic portfolio by identifying SPRAVATO’s overall scenario in treatment-resistant depression.

key question

  • What is the product type, route of administration and mechanism of action of SPRAVATO?

  • What is the clinical study status of the SPRAVATO study in treatment-resistant depression and the study completion date?

  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the development of SPRAVATO?

  • What are the key designations SPRAVATO has received for treatment-resistant depression?

  • What is SPRAVATO’s forecast market scenario for Treatment-Resistant Depression?

  • What are SPRAVATO’s projected sales in the top seven countries including the United States, Europe (Germany, France, Italy, Spain and the United Kingdom) and Japan?

  • What other new products are available and how do they compete with SPRAVATO for treatment-resistant depression?

  • What are the late-phase therapies under development to treat treatment-resistant depression?

For more information on this Drug Pipelines Report, visit https://www.researchandmarkets.com/r/8uhl4o

Also Read :  POLL Global 2023 economic view downgraded, at odds with market optimism

Leave a Reply

Your email address will not be published.